【导读】胜通能源筹划易主，12月5日起停牌 中国基金报记者 夏天 上市三年后， 胜通能源 （证券代码：001331）拟易主。 12月5日午间，胜通能源公告称，公司控股股东、实际控制人魏吉胜已签署了股份转让意向书，该事项可能导致公司控股股东、实际控制人 发生变更。 公开资料显示，胜通能源成立于2012年，2022年9月在深交所挂牌上市，主营业务为LNG（液化天然气）的采购、运输、销售以及原油、 普货的运输服务。 截至2025年三季度末，魏吉胜直接持有胜通能源1.04亿股，持股占比 为 36.97%，系公司第一大股东，期末参考市值约 为 14.4亿元。 | 十大股东明细 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 时间范围 | | | | | | | 11时间排序 | [ = =出到excel | | 2025年三季报 | | | | | | | | 查看图形 | | 股东各称 | 股东性质 | 期末参考市值 (亿元) | 持股数量(股) | 持股比例 (%) | 較上期持股变 动数(設) | 持設比例变动 ...

Core Viewpoint - The actual controller of Guosheng Securities will change to Jiangxi Provincial State-owned Assets Supervision and Administration Commission following a free transfer of shares from its controlling shareholder, Jiangxi Jiaotou [2] Group 1: Share Transfer Details - Guosheng Securities announced that its controlling shareholder, Jiangxi Jiaotou, will transfer 90% of its shares to Jiangxi Provincial State-owned Assets Supervision and Administration Commission without compensation [2] - The transfer has been approved by the Jiangxi Provincial Government and will result in Jiangxi Provincial State-owned Assets Supervision and Administration Commission directly holding the shares [2] Group 2: Ownership Structure - After the transfer, Jiangxi Provincial State-owned Assets Supervision and Administration Commission will hold 90% of Jiangxi Jiaotou's shares, while Jiangxi Jiaotou's ownership stake in Guosheng Securities will remain unchanged [2] - The controlling shareholder of Guosheng Securities will still be Jiangxi Jiaotou, but the actual controller will shift from Jiangxi Provincial Department of Transportation to Jiangxi Provincial State-owned Assets Supervision and Administration Commission [2]

人民财讯10月31日电，中元股份（300018）10月31日公告，10月30日，公司实控人尹健等8人与朱双 全、朱顺全签订《表决权委托协议》，尹健等8人将合计持有中元股份1.01亿股股份的表决权委托给朱 双全、朱顺全行使。同日，朱双全、朱顺全、朱梦茜与尹健等8人签署一致行动协议，约定表决权委托 期间，尹健等8人成为朱双全、朱顺全、朱梦茜的一致行动人。《表决权委托协议》生效后，朱双全、 朱顺全持有上市公司的表决权比例为20.71%。截至10月30日，朱梦茜直接持有上市公司的股权比例为 4.92%。10月30日，朱双全、朱顺全、朱梦茜签署《一致行动协议》，朱双全、朱顺全、朱梦茜为一致 行动人，合计持有上市公司的表决权比例为25.63%，上市公司实控人变更为朱双全、朱顺全及朱梦 茜。公司股票自11月3日起复牌。 ...

Core Viewpoint - The recent criminal detention of Xu Xiren, the chairman and president of Beijing University Pharmaceutical, raises significant concerns regarding the company's management stability and future operations [1][10]. Group 1: Management Changes - Xu Xiren was recently detained, which has led to a temporary delegation of his responsibilities to other executives [1][10]. - The company underwent a major management reshuffle earlier this year, with several key executives resigning or being removed from their positions [11][15]. Group 2: Ownership and Financial Transactions - Xu Xiren acquired control of Beijing University Pharmaceutical for a nominal price of 1 yuan, gaining a 22.22% stake in the company through a complex transaction involving the acquisition of Southwest Synthetic Pharmaceutical Group [4][6]. - The deal included the transfer of over 24 billion yuan in debt, which poses potential financial risks for the company [7][8]. Group 3: Business Challenges - The company is facing pressure to dissociate from its historical ties to Peking University and Ping An Insurance, which may impact its brand and business operations [9][10]. - A significant portion of the company's revenue has been historically dependent on its partnership with Peking University International Hospital, which has recently been terminated, leading to potential revenue losses estimated at 6 billion yuan for the latter half of 2025 [10][9]. Group 4: Market and Financial Performance - For the year 2024, the company reported total revenue of 2.06 billion yuan and a net profit of 127 million yuan, indicating a challenging financial landscape ahead [10]. - The anticipated revenue decline due to the termination of key partnerships could lead to a significant drop in net profit, with projections indicating a decrease of approximately 680 million yuan starting in 2026 [10].

Core Viewpoint - The board of North China Pharmaceutical (000788.SZ) has proposed to remove director Mao Run due to his resignation from Southwest Synthesis Pharmaceutical Group, which he opposed, citing legal grounds for his dismissal [1][2][4]. Group 1: Board Changes - Mao Run was proposed to be removed from the board as he no longer represents Southwest Synthesis due to his resignation from executive roles [2][3]. - The board voted to remove Mao Run with 8 votes in favor and 1 against, highlighting a significant shift in board composition following the change in actual control of the company [2][6]. - The newly elected non-independent director is Huang Lianjun, who has connections to the new controlling shareholder [3][4]. Group 2: Changes in Control - The actual control of North China Pharmaceutical changed hands in December 2023 when New Advantage acquired 100% of Southwest Synthesis from the Ping An Group [4][5]. - Following the acquisition, there have been multiple personnel changes within the board, indicating a strategic shift under new management [6][7]. - The new controlling entity has maintained a consistent operational strategy despite changes in ownership, focusing on core pharmaceutical areas [7][8]. Group 3: Financial Performance - North China Pharmaceutical's revenue from pharmaceutical distribution increased to nearly 70% in 2024, reflecting a strategic focus on this segment [8]. - The company's revenue decreased from 2.237 billion yuan in 2021 to 2.060 billion yuan in 2024, while net profit rose from 43.14 million yuan to 138 million yuan during the same period, marking a historical high [7][8].